Plain-English translation of NCT06730009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing Allogeneic Magicell-NK, a new type of immune cell therapy, combined with standard chemotherapy in patients who have just had surgery for pancreatic cancer or bile duct cancer. The study wants to find the safest dose of this medication and whether adding it to chemotherapy helps prevent cancer from coming back better than chemotherapy alone.
Pancreatic and bile duct cancers are aggressive and often return even after surgery and chemotherapy. This medication is designed to help the body's immune system fight any remaining cancer cells, and researchers hope it may improve survival and reduce the chance of the cancer returning.
You likely qualify if…
You likely don't qualify if…
You will receive 12 weeks of standard chemotherapy. Depending on which group you are assigned to, you may also receive 6 intravenous infusions of the new immune cell medication on the 11th day of each chemotherapy cycle. You will have regular clinic visits and blood tests to monitor your safety and how well the treatment is working. The trial is divided into two phases: Phase I will test which dose of the medication is safest, and Phase II will compare the combination therapy to chemotherapy alone.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Taiwan